| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Neuropace, Inc.$17.11
+0.14 (+0.82%)
D 29Pipeline Score MedTech · Commercial
Market Cap
576.87 M
EPS
-0.65
P/E Ratio
-
Value Trade
2.84 M
SEC Financials
Q1 2026Dilution Risk
Revenue
22.07 M
R&D Expenses
7.19 M
Operating CF
-5.90 M
Total Assets
98.90 M
Total Liabilities
84.44 M
Equity
14.45 M
D/E Ratio
12,345
9.23 %
Week
2.61 %
1 Month
17.5 %
3 Month
25.43 %
6 Month
-25.27 %
5 Year
-27.23 %
All Time
Cash Data
Cash Position
53.98 M
Monthly Burn
1.97 M
Runway
25.7 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
179.51 K
52 Week Range
7.56 - 19.60
% held by Insiders
23.42 %
% held by Institutions
73.71 %
Enterprise Value
593.35 M
Total Shares
34.07 M
Short %
2.35 %
Float Shares
23.30 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D29
Pipeline Score $124M
Pipeline ValueValuation Signal
2
Drugs Scored0.2x
rNPV / MCap Top 32%
Micro Cap (rank 620 of 911)
Percentile RankNeuropace, Inc. faces pipeline headwinds (29/100), with $310M risk-adjusted pipeline value, led by external Responsive Neurostimulator System in Epilepsy (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| external Responsive Neurostimulator System Unknown | Epilepsy | Phase 2 | NCT00158067 | 12% | $306M | COMPLETED | 150 | - | - | Mar 1, 2008 | - | Aug 26, 2010 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
RNS System | drug-resistant focal epilepsy and idiopathic generalized epilepsy | — | 2026-04-27 | 82% median seizure reduction; 77% median reduction in GTC seizures; injury events declined by approximately 30%; use of a benzodiazepine as a rescue medication for a GTC seizure were 44% lower Read More | NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026 Read More | |
RNS System | drug-resistant focal epilepsy and idiopathic generalized epilepsy | — | 2026-04-27 | 82% median seizure reduction; 77% median reduction in GTC seizures; injury events declined by approximately 30%; use of a benzodiazepine as a rescue medication for a GTC seizure were 44% lower Read More | NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026 Read More | |
RNS System | drug-resistant focal epilepsy and idiopathic generalized epilepsy | — | 2026-04-27 | 82% median seizure reduction; 77% median reduction in GTC seizures; injury events declined by approximately 30%; use of a benzodiazepine as a rescue medication for a GTC seizure were 44% lower Read More | NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NPCE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NPCE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NPCENeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care
NeuroPace has received FDA approval for its ECoG Assistant™, a device designed to enhance AI-driven care for epilepsy patients. This approval is a significant milestone for the company, indicating progress in innovative treatment options for epilepsy. The ECoG Assistant™ aims to improve patient outcomes through advanced technology.
Read more →NPCENeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting
NeuroPace is set to showcase its advancements in responsive neuromodulation at the upcoming 2026 ASSFN Meeting. The event will highlight the expanding applications of this technology in neurosurgery. Further details on the specific presentations or innovations to be discussed were not provided in the article.
Read more →NPCENeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
NeuroPace has released its financial results for the first quarter of 2026 and has increased its revenue guidance for the year. The report indicates a positive outlook for the company's financial performance. However, specific details on revenue figures or factors influencing the guidance were not provided.
Read more →NPCEDocument NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance Total revenue of $22.1 million Raises full year 2026 guidance to $99 million to $101 million, up from $98 million to $100 m
NeuroPace, Inc. has reported its first quarter 2026 financial results, highlighting total revenue of $22.1 million, marking a year-over-year growth of 20.1%. The company has raised its full-year revenue guidance for 2026 to between $99 million and $101 million, based on expectations of 21% to 23% growth in its core RNS revenue. However, NeuroPace reported a net loss of $6.7 million in the quarter despite these positive revenue figures, alongside an increase in operating expenses.
Read more →NPCENeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026
NeuroPace, Inc. will report its financial results for Q1 2026 on May 12, 2026, after market close. A conference call will follow at 1:30 p.m. PT, accessible via webcast or telephone. NeuroPace specializes in innovative medical devices for epilepsy treatment, particularly through its RNS System, which provides personalized care.
Read more →NPCENeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026
NeuroPace has published 3-year results from its RNS System Post-Approval Study, showing an 82% median seizure reduction in drug-resistant focal epilepsy. Additionally, the NAUTILUS trial presented 12- and 18-month data, revealing a 77% median reduction in generalized tonic-clonic seizures. These findings underscore NeuroPace's leadership in clinical evidence for epilepsy treatments.
Read more →NPCEDocument NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook Reported quarterly revenue of $26.6 million in Q4 2025 representing 24% growth Reiterates previously issued 2026
NeuroPace, Inc. reported strong financial results for Q4 and the full year 2025, highlighting a 24% growth in quarterly revenue to $26.6 million. The company reiterated its 2026 outlook, expecting 20% to 22% growth in RNS revenue. Efforts to secure regulatory approval for expanding indications and favorable reimbursement updates mark significant strategic progress. Nonetheless, the company still faces challenges, with ongoing negative adjusted EBITDA and rising operating expenses.
Read more →NPCENeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
NeuroPace, Inc. reported preliminary unaudited results for Q4 and FY 2025, showing significant revenue growth. The company anticipates continued growth in 2026, with expected revenues between $98 million and $100 million. However, it also announced the early termination of its partnership with DIXI Medical, which will affect future financial reporting.
Read more →NPCENeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference
NeuroPace, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The management team will discuss their innovative RNS System, designed to improve the treatment of epilepsy. The presentation will be available via live webcast and will include investor meetings.
Read more →NPCENeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy
NeuroPace, Inc. has submitted a PMA Supplement to the FDA to expand its RNS System indication for patients with drug-resistant idiopathic generalized epilepsy (IGE). This application is backed by promising results from the NAUTILUS trial, which reported a 77% median reduction in generalized tonic-clonic seizures. The RNS System has received Breakthrough Device Designation, highlighting its potential impact on treatment options for this patient group.
Read more →NPCENeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting
NeuroPace, Inc. will present its RNS System and AI platform at the 2025 AES Annual Meeting, highlighting new clinical data and AI advancements. The company aims to demonstrate how these innovations lead to significant seizure reductions and enhance physician confidence in treatment. Attendees can expect hands-on demonstrations and insights into the future of epilepsy care.
Read more →NPCEDocument NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance Reported record quarterly revenue of $27.4 million in Q3 2025 representing 30% growth Increased full-year 2025 revenue g
NeuroPace, Inc. reported its third-quarter 2025 financial results, highlighting a record revenue of $27.4 million, marking a 30% year-over-year growth. The company also increased its full-year revenue guidance to between $97 million and $98 million, with an impressive gross margin of 77.4%. Additionally, NeuroPace plans to submit a PMA supplement to the FDA for the RNS System by the end of 2025, focusing on the idiopathic generalized epilepsy indication. However, the company experienced a net loss of $3.5 million, raising concerns about future profitability amidst rising operational costs.
Read more →NPCENeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
NeuroPace, Inc. reported a record revenue of $23.5 million for Q2 2025, marking a 22% increase year-over-year. The company has raised its full-year revenue guidance to between $94 million and $98 million. Despite these positive financial results, NeuroPace experienced an increase in operating and net losses. The company is on track to submit data for FDA indication expansion in the latter half of 2025.
Read more →NPCEDocument NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance Reported record quarterly revenue of $23.5 million in Q2 2025 Increased full-year 2025 revenue guidance to between $94
NeuroPace, Inc. reported strong financial results for Q2 2025 with a record revenue of $23.5 million, marking a 22% year-over-year growth. The company has raised its full-year revenue guidance to between $94 million and $98 million, alongside a robust gross margin of 77.1%. While the NAUTILUS study for the RNS therapy showed promising secondary effectiveness results, the company continued to face challenges with a net loss of $8.7 million and increased operating expenses due to one-time costs. Overall, NeuroPace remains well-positioned for future growth despite these financial hurdles.
Read more →NPCE▲ +5.6%on this news
NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases
NeuroPace, Inc. has praised the Centers for Medicare & Medicaid Services (CMS) for deciding not to change the reimbursement structure for its RNS System used in epilepsy treatment. This decision ensures that hospitals can continue providing care to Medicare beneficiaries without disruption. NeuroPace remains dedicated to collaborating with CMS on reimbursement improvements to enhance access for patients.
Read more →NPCENeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025
NeuroPace, Inc. has announced that it will report its second quarter financial results for 2025 on August 12, 2025, after market close. The company will host a webcast conference call at 1:30 p.m. Pacific Time to discuss these results. Interested investors can access the live webcast or participate via telephone. NeuroPace is recognized for its innovative RNS System, aimed at improving care for patients with epilepsy.
Read more →NPCENeuroPace Announces Strategic CFO Transition
NeuroPace, Inc. has appointed Patrick F. Williams as its new Chief Financial Officer, effective June 20, 2025. Williams, who has over 25 years of experience in financial management within medical device companies, replaces Rebecca Kuhn, who will transition to an advisory role. The leadership change comes as NeuroPace aims to expand access to its RNS System for epilepsy treatment.
Read more →NPCENeuroPace Announces Strategic CFO Transition Appoints Patrick F. Williams as Chief Financial Officer Williams Brings a Track Record of Leading Medical Device Public Companies as CFO Rebecca Kuhn Departing Company and Wil
NeuroPace, Inc. has appointed Patrick F. Williams as its new Chief Financial Officer, effective June 20, 2025, following the departure of Rebecca Kuhn, who will remain in an advisory role. Williams brings over 25 years of experience in financial and operational management within the medical device industry, most recently serving as CFO for STAAR Surgical. The leadership transition is viewed positively as the company seeks to expand access to its RNS System, which provides treatment for drug-resistant epilepsy. However, challenges relating to market adoption and regulatory compliance have been acknowledged.
Read more →NPCENeuroPace Secures Up to $75 Million in Debt Financing
NeuroPace, Inc. has secured a $75 million credit facility with MidCap Financial, consisting of a $60 million term loan and a $15 million revolving credit line. The funds will be used to repay an existing loan and support various growth initiatives, including expanding patient access to their RNS System. The new financing structure is expected to enhance the company's financial flexibility.
Read more →NPCE▼ -28.4%on this news
NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study
NeuroPace has announced preliminary results from the NAUTILUS study, which evaluated the RNS System for drug-resistant idiopathic generalized epilepsy. The study met its primary safety endpoint but did not achieve statistical significance for the primary effectiveness endpoint in the overall population. However, a significant response was noted in a subgroup of patients. The results indicate the potential for personalized treatment options.
Read more →NPCENeuroPace Reports First Quarter 2025 Financial Results
NeuroPace, Inc. reported strong financial results for Q1 2025, with revenues reaching $22.5 million, a 24% increase from the previous year. The company raised its full-year guidance to between $93 million and $97 million, attributed to robust demand for its RNS System. Positive data from a three-year study on the efficacy of their therapy was also presented. However, the company recorded a net loss, which, while reduced from the prior year, signals ongoing financial pressures amid increased operating costs and a strategic refocus on their core product line.
Read more →NPCEDocument NeuroPace Reports First Quarter 2025 Financial Results Reported record quarterly revenue of $22.5 million in Q1 2025, driven by increasing market demand for core RNS System products Increased full-year 2025 reve
NeuroPace, Inc. has announced its financial results for Q1 2025, reporting a record quarterly revenue of $22.5 million, reflecting a 24% year-over-year growth. The company has increased its full-year revenue guidance to between $93 and $97 million, driven by strong sales of its RNS System products. The gross margin improved to 77%, surpassing expectations, indicating better profitability. Despite these positive outcomes, the company reported a net loss of $6.6 million for the quarter, although it is an improvement from the previous year.
Read more →NPCENeuroPace Provides Update on Tariff Status
NeuroPace, Inc. has provided an update regarding the impact of tariffs on its operations, indicating that the effects will be minimal. The company manufactures most of its devices in the U.S. and expects no significant changes to its gross margin for 2025. Additionally, NeuroPace will report its first quarter financial results on May 13, 2025.
Read more →NPCENeuroPace Provides Update on Tariff Status Minimal expected impact to operations and financial results Company to report first quarter 2025 financial results on
NeuroPace, Inc., a medical device company, updated investors on its tariff exposure, indicating minimal expected impact on operations and financial results. The company manufactures and sells most of its devices in the United States and anticipates no material changes to its gross margin for fiscal year 2025. Furthermore, NeuroPace will report its first-quarter financial results for 2025 on May 13, 2025, and has reiterated its gross margin guidance despite the varying external trade policies.
Read more →NPCE▼ -9.8%on this news
NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting
NeuroPace, Inc. announced positive three-year data from its Post-Approval Study of the RNS System, showing an 82% median reduction in seizures for adults with drug-resistant focal epilepsy. The results were presented at the AAN Annual Meeting, highlighting the RNS System's effectiveness and safety. This study is noted as the largest FDA-reviewed trial in neuromodulation for epilepsy.
Read more →NPCENeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting
NeuroPace, Inc. will present data from its Post-Approval Study of the RNS System at the AAN 2025 Annual Meeting. The RNS System is designed for adults with drug-resistant focal epilepsy, addressing a critical need for effective treatments. The presentation aims to share insights that could enhance patient care and outcomes.
Read more →NPCENeuroPace Announces Refocusing of Product Portfolio Beginning of Wind Down of Stereo EEG (SEEG) Distribution Relationship in Q4 2025 Maintaining 2025 Revenue Guidance No Change to Long-Range Plan Expectations of Cash Flo
NeuroPace, Inc. announced its strategic refocusing on the RNS System product line, leading to the termination of its SEEG distribution agreement effective Q4 2025. The company is aiming to concentrate resources on expanding its growth opportunities and improving the standard of care for drug-resistant epilepsy patients. Despite the changes, NeuroPace has maintained its revenue guidance for 2025 and continues to project a cash flow breakeven by 2027, alongside plans for indication expansion and the launch of new AI products. CEO Joel Becker expressed confidence in this strategic shift to enhance operational efficiency and market presence.
Read more →NPCENeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference
NeuroPace, Inc. announced its management team will present at the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025. The event will also include investor meetings, emphasizing the company's focus on engaging with stakeholders. NeuroPace is dedicated to improving the lives of individuals with epilepsy through its innovative RNS System, the first platform providing personalized, real-time treatment. Attendees can access the presentation via a live webcast, with a replay available for 90 days afterwards.
Read more →NPCEDocument NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results Record quarterly revenue of $21.5 million in Q4 2024 Full-year 2025 revenue guidance of $92 to $96 million Completed an underwritten public o
NeuroPace reported a record quarterly revenue of $21.5 million for Q4 2024, representing a year-over-year growth of 19%. The company provided a strong revenue guidance for full-year 2025, expecting between $92 million and $96 million. Notably, management emphasized the ongoing progress in projects such as Project CARE and the development of AI-enabled software tools. Despite these positive indicators, NeuroPace recorded a net loss of $5.3 million in Q4 2024 and an increase in operating expenses, raising concerns over future profitability.
Read more →NPCENeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results
NeuroPace, Inc. reported its financial results for Q4 and full year 2024, highlighting a record revenue of $21.5 million for Q4, and a total revenue increase of 22% for the year to $79.9 million. The company successfully completed a public offering to strengthen its balance sheet, using part of the funds to repurchase shares. Despite the positive revenue growth and strong gross margin, NeuroPace continues to face net losses, reporting a Q4 net loss of $5.3 million and a total annual net loss of $27.1 million. The company anticipates revenues between $92 to $96 million for 2025, driven mainly by their RNS System sales.
Read more →NPCE▼ -8.8%on this newsshared move
NeuroPace to Present at the Leerink Partners Global Healthcare Conference
NeuroPace, Inc. has announced its participation in the Leerink Partners 2025 Global Healthcare Conference, where management will present at 4:20 PM ET on January 10, 2025. The conference will provide an opportunity for NeuroPace to showcase its innovative RNS System, designed to treat epilepsy through personalized therapy. Additionally, the management team will conduct investor meetings, highlighting the commercial stage progress of the company. The presentation will be available via live webcast and will be accessible for two weeks post-event.
Read more →NPCE▲ +5.8%on this news
NeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Stock from KCK Ltd. Mountain View, Calif.
NeuroPace, Inc. has successfully completed the repurchase of 5.3 million of its common shares from KCK Ltd., enhancing their financial position. This strategic move utilized funds from a recent public offering, allowing the company to strengthen its balance sheet and support its operations towards cash flow breakeven. The CEO expressed satisfaction with investor interest and emphasized the company's commitment to addressing epilepsy challenges through innovative solutions. Despite these positive developments, the company faces uncertainties related to market acceptance and potential operational risks.
Read more →NPCENeuroPace to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
NeuroPace, Inc. has announced that it will report its financial results for the fourth quarter and full year of 2024 on March 4, 2025. Following the announcement, the company will hold a management webcast and conference call to discuss the results, open to interested investors. NeuroPace is dedicated to improving the quality of life for epilepsy patients and aims to provide innovative solutions for those suffering from drug-resistant cases.
Read more →NPCE▲ +9.2%on this newsshared move
NeuroPace Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
NeuroPace, Inc. completed an underwritten public offering of 7,475,000 shares of common stock at a price of $10.00 per share, raising approximately $74.8 million. The company plans to allocate around $49.5 million of the proceeds to repurchase shares owned by a significant stockholder, KCK Ltd. The remainder of the funds will be used for general corporate purposes, including R&D expenses and working capital. NeuroPace aims to enhance the quality of care for epilepsy patients through its novel RNS System.
Read more →NPCENeuroPace Announces Pricing of Public Offering of $65 Million of Common Stock
NeuroPace, Inc. has priced an underwritten public offering of 6.5 million shares at $10.00 per share, expected to raise $65 million. The offering is scheduled to close on February 18, 2025, and will primarily finance a share repurchase from a significant stakeholder as well as support general corporate purposes, including clinical trials. Notably, NeuroPace's RNS System is the only brain-responsive platform marketed for treating epilepsy, which could enhance patient care in this space.
Read more →NPCENeuroPace Announces Proposed Public Offering of $65 Million of Common Stock
NeuroPace, Inc. has announced a proposed public offering of $65 million in common stock, which is expected to boost its financial resources. A significant portion of the proceeds will be used to repurchase shares from its stockholder KCK Ltd., while the remaining funds will support various corporate needs, including R&D and debt reduction. However, the completion of the offering depends on market conditions, introducing some uncertainty regarding the timing and final outcome.
Read more →NPCENeuroPace Announces Upcoming Oral Presentation of Data from the Post-Approval Study of the RNS System at the American Academy of Neurology 2025 Annual Meeting Being Held April 5th – 9th
NeuroPace, Inc. has announced that their data from the Post-approval Study of the RNS System will be presented as an oral presentation at the upcoming American Academy of Neurology (AAN) 2025 Annual Meeting. The session will focus on epilepsy clinical outcomes, with the presentation given by Dr. Dawn Eliashiv. The RNS System is designed to provide personalized treatment for patients with drug-resistant epilepsy, indicating its potential for improving patient outcomes.
Read more →NPCENeuroPace Issues 2025 Financial Guidance Targets 2025 revenue guidance of $92 million to $96 million 2025 gross margin guidance of 73% to 75% Three-year targets of 20% revenue CAGR and achievement of cash flow breakeven
NeuroPace, Inc. has issued its financial guidance targets for 2025, projecting revenue between $92 million and $96 million, with gross margins anticipated at 73% to 75%. The company aims for a compound annual growth rate (CAGR) of 20% over the next three years while targeting cash flow breakeven. NeuroPace focuses on becoming a recognized leader in drug-resistant epilepsy therapy through its RNS System, which offers personalized treatment for epilepsy patients. However, potential risks include market acceptance, regulatory compliance, and operating expenses that may exceed expectations.
Read more →NPCENeuroPace Issues 2025 Financial Guidance Targets
NeuroPace, Inc. (Nasdaq: NPCE) recently outlined its 2025 financial guidance, projecting revenues between $92 million and $96 million, alongside a gross margin of 73% to 75%. The company also set ambitious strategic objectives aimed at becoming a leader in drug-resistant epilepsy therapy. This includes expanding its patient demographic and improving product efficiency and accessibility through various campaigns. However, NeuroPace acknowledges potential risks, including the variability of actual operating results and challenges related to regulatory compliance.
Read more →NPCENeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business Updates Preliminary unaudited revenue expected to be between $21.0 million and $21.5 million for Q4 2024, and
NeuroPace has announced its preliminary unaudited revenue for the fourth quarter and full year of 2024, estimating Q4 revenues between $21.0 million and $21.5 million, and total annual revenues between $79.4 million and $79.9 million. The company reported a revenue growth of over 20% for the year, alongside reduced cash burn while investing in future growth. Additionally, Scott Huennekens has been appointed to the Board of Directors, bringing extensive experience in the medical device sector. NeuroPace is also preparing for an Investor Day and will present at the J.P. Morgan Healthcare Conference in January 2025.
Read more →NPCE▼ -7.6%on this news
NeuroPace to Present at the 43rd Annual J.P. Morgan Healthcare Conference
NeuroPace, Inc. announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, where its management will present on January 15, 2025, in San Francisco. The presentation will emphasize the company's focus on epilepsy treatment using its innovative RNS System, which provides personalized, real-time intervention. Additionally, NeuroPace plans to host investor meetings to foster engagement and discuss its advancements in medical technology.
Read more →NPCENeuroPace to Host Investor Day on January 28th in New York City
NeuroPace, Inc. will host an Investor Day on January 28, 2025, in New York City. The event aims to provide updates on the company's RNS technology and future plans, including discussions on market, product, and clinical strategies. Attendees will hear from management and key opinion leaders, as well as a patient sharing personal experiences with the RNS System. This highlights NeuroPace's commitment to improving outcomes for individuals with epilepsy.
Read more →NPCE▼ -6.2%on this news
NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting
NeuroPace, Inc. announced its significant participation in the upcoming 2024 American Epilepsy Society Annual Meeting, showcasing its RNS System. Attendees can explore new clinical data, AI innovations, and the therapy's effectiveness, such as an 82% seizure reduction at three years. The company will host demonstrations and panels aimed at enhancing the understanding and application of responsive neuromodulation therapies for epilepsy. This event is a pivotal opportunity for clinicians to engage with the latest developments in epilepsy treatment.
Read more →NPCE▲ +5.7%on this newsshared move
NeuroPace Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut Syndrome
NeuroPace, Inc. has announced the successful completion of enrollment and implant procedures for its feasibility study of the RNS® System aimed at treating Lennox-Gastaut Syndrome (LGS), a severe form of childhood epilepsy. The study, supported by a $9.3 million NIH grant, enrolled 20 patients with drug-resistant generalized onset seizures. NeuroPace's RNS System has shown promise in treating focal onset seizures, and this research aims to evaluate its efficacy in LGS. Participation in the study will transition to a long-term follow-up period of 18 months after the initial year-long open label period.
Read more →NPCENeuroPace Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
NeuroPace, Inc. reported strong financial results for Q3 2024, achieving record revenue of $21.1 million, reflecting a 28% increase from the previous year. The company decreased its cash burn to $1.8 million, demonstrating ongoing operational efficiency. Additionally, NeuroPace raised its full-year revenue guidance to a range of $78 million to $80 million, indicating positive expectations for continued growth. The company also announced strategic expansions in its management team to leverage its performance and growth opportunities.
Read more →NPCEDocument NeuroPace Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Grew revenue 28% year-over-year to $21.1 million in Q3 2024 Increased full-year 2024 revenue guidance to $78 million to
NeuroPace reported its financial results for the third quarter of 2024, showcasing a revenue increase of 28% year-over-year to $21.1 million. The company also raised its full-year revenue guidance to between $78 million and $80 million, reflecting a strong operational performance. Notably, the cash burn decreased to $1.8 million, indicating improved financial management. In addition, the company reported positive data from its ongoing safety and effectiveness studies on its RNS System.
Read more →NPCENeuroPace Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal Epilepsy
NeuroPace, Inc. has announced the submission of three-year safety and effectiveness data for its RNS System to the FDA, as part of a prospective Post-Approval Study (PAS). This study, which involved over 300 patients across 30 Comprehensive Epilepsy Centers, is the largest of its kind in neuromodulation for drug-resistant focal epilepsy. NeuroPace aims to provide reliable clinical evidence to support physicians in their treatment of epilepsy patients. The ongoing study will continue to a five-year follow-up endpoint as outlined in the device's initial FDA approval requirements.
Read more →NPCENeuroPace to Report Third Quarter 2024 Financial Results on November 12, 2024
NeuroPace, Inc. will report its financial results for the third quarter of 2024 on November 12, 2024. The company specializes in medical devices aimed at treating epilepsy and will hold a webcast conference call at 1:30 p.m. PT to discuss these results. Investors can access the call via a live and archived webcast, or by telephone. NeuroPace is known for its innovative RNS System that delivers personalized epilepsy treatment.
Read more →NPCENeuroPace Continues to Strengthen Management Team
NeuroPace, Inc. has announced the appointment of Amy Treadwell as Vice President of Human Resources to strengthen its management team. The company emphasizes its growth opportunities and positions itself for better access to its RNS therapy. Recent additions to the leadership team include Brett Wingeier and Katie Keller in key roles. NeuroPace aims to improve treatment for epilepsy patients, but potential market and regulatory challenges remain.
Read more →NPCENeuroPace Strengthens Management Team with Two Key Appointments
NeuroPace, Inc. has announced the appointment of Brett Wingeier as the Vice President of Research and Development and Katie Keller as the Vice President of Marketing. Wingeier has a rich background in neurotech and was instrumental in developing NeuroPace's RNS System, while Keller brings significant marketing expertise from her tenure at Boston Scientific. Both will focus on expanding the capabilities of RNS therapy and increasing market accessibility for epilepsy treatment. Their addition to the team is seen as a strategic move to enhance the company’s operational goals and treatment offerings.
Read more →NPCENeuroPace Announces Participation at Two Upcoming Healthcare Investor Conferences
NeuroPace, Inc. announced its participation in two upcoming healthcare investor conferences in September 2024. The company will host one-on-one meetings at the Lake Street Big8 Best Ideas Growth Conference and participate in a fireside chat at the Cantor Global Healthcare Conference. Both events will take place in New York, providing NeuroPace an opportunity to engage with investors and showcase its innovative RNS System aimed at transforming the lives of patients with epilepsy.
Read more →NPCE▼ -5.7%on this newsshared move
NeuroPace to Participate in Upcoming Healthcare Conferences in September
NeuroPace, Inc. announced its participation in two key healthcare conferences in September. The company will hold one-on-one investor meetings at the Wells Fargo 2024 Healthcare Conference and present at the Morgan Stanley 22nd Annual Global Healthcare Conference. CEO Joel Becker and CFO Rebecca Kuhn will engage in a fireside chat and also host further investor meetings. This initiative emphasizes NeuroPace's commitment to transforming epilepsy treatment through its innovative RNS System.
Read more →NPCE▲ +5.5%on this news
NeuroPace Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
NeuroPace, Inc. reported a strong second quarter for 2024, with revenues rising to $19.3 million, a 17% increase over the same period in 2023. The company has raised its revenue guidance for the full year to a range of $76 million to $78 million, reflecting optimism about future sales growth driven by their RNS System and DIXI Medical products. Improvements in gross margin and reductions in cash burn indicate effective operational strategies. However, rising operating expenses and ongoing net losses remain concerns that could affect future performance.
Read more →NPCE▲ +5.5%on this news
Document NeuroPace Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Revenue grew to $19.3 million in Q2 2024, a 17% increase over Q2 2023 Increased full-year 2024 revenue guidance to $76
NeuroPace, Inc. reported a significant revenue increase in the second quarter of 2024, reaching $19.3 million, a 17% rise from the same period last year. The company has also raised its full-year revenue guidance to between $76 million and $78 million, indicating optimism for continued growth. An expansion in gross margin to 73.4% was achieved alongside a decrease in cash burn to $4 million. Executives remain focused on increasing the adoption of their RNS therapy for epilepsy patients.
Read more →NPCE▲ +10.6%on this news
NeuroPace to Report Second Quarter 2024 Financial Results on August 13, 2024
NeuroPace, Inc. announced it will report its financial results for the second quarter of 2024 after market close on August 13, 2024. The company, known for its innovative RNS System designed to help patients with epilepsy, will host a webcast of the conference call starting at 1:30 p.m. PT. Investors can access the call either via a live webcast or by telephone. The results are anticipated to provide insights into the company's performance and ongoing commitment to improving patient care.
Read more →NPCENeuroPace to Participate in Two Healthcare Conferences in May
NeuroPace, Inc., a medical device company focusing on epilepsy treatment, announced it will participate in two healthcare conferences in May 2024. The management team will be involved in the Wells Fargo 2024 West Coast MedTech Tour and the Leerink Partners Healthcare Crossroads Conference. CEO Joel Becker will give a corporate presentation and engage in one-on-one investor meetings during the events. These opportunities highlight NeuroPace's commitment to transforming epilepsy care through its innovative RNS System.
Read more →NPCE▼ -5.3%on this news· ran to -40% by day 1
NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate Update
NeuroPace, Inc. reported a 25% increase in revenue for Q1 2024, totaling $18.1 million, driven by strong sales of its RNS System and DIXI Medical products. The company has extended the maturity date of its term loan to September 30, 2026, which bolsters its financial flexibility. NeuroPace continues to expect a full-year revenue range of $73 million to $77 million despite facing a decline in replacement implant revenue. Management remains focused on expanding access to the RNS therapy for drug-resistant epilepsy patients through initiatives such as the Project CARE pilot program.
Read more →NPCE▼ -5.3%on this news· ran to -40% by day 1
Document NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate Update Revenue increased to $18.1 million in Q1 2024, a 25% increase over Q1 2023 Extended the maturity date of the Company's term lo
NeuroPace, Inc. reported its financial results for the first quarter of 2024, highlighting a revenue increase of 25% to $18.1 million compared to the same period in 2023. The company has extended the maturity date of its term loan to September 30, 2026, which improves its financial positioning. NeuroPace continues to forecast full-year revenue between $73 million and $77 million and has reported strong growth in sales of its RNS System and DIXI Medical products. Nonetheless, the company grapples with a decrease in replacement implant revenue and increased operating expenses.
Read more →NPCENeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
NeuroPace, Inc. has announced that it will report its first quarter 2024 financial results on May 8, 2024, after market close. Following the results, the company's management will host a conference call that is accessible via webcast and telephone. The call aims to keep investors informed about NeuroPace's operations and future strategies. NeuroPace is dedicated to developing innovative solutions for epilepsy treatment through its unique RNS System, which provides real-time therapies to patients.
Read more →NPCENeuroPace to Present at the Needham 23rd Annual Healthcare Conference
NeuroPace, Inc. announced its participation in the Needham 23rd Annual Healthcare Conference, scheduled to be held virtually from April 8-11, 2024. CEO Joel Becker will present a corporate overview and engage in one-on-one meetings with investors during the event. The company's focus is on improving treatments for individuals living with epilepsy through its unique, brain-responsive RNS system. A live webcast of the presentation will be available, and a recorded replay will be accessible afterward on their investor website.
Read more →NPCEDocument NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million Revenue increased to $18.0 million in Q4 2023, a 41% increase over Q4 2022 Revenue increased to $65.4 million in 2023, a 44% increase over 2022
NeuroPace reported a record revenue of $65.4 million for the full year 2023, marking a 44% increase from the previous year. The company also announced guidance for 2024 revenue, projecting between $73 million and $77 million. Key strategic initiatives include the launch of Project CARE to increase access for epilepsy patients and the completion of the NAUTILUS study for FDA submission. Despite these successes, the company anticipates continued declines in replacement implant revenue going forward.
Read more →NPCENeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
NeuroPace, Inc. reported record revenue of $65.4 million for the year 2023, marking a 44% increase from 2022. The company also recorded $18.0 million in Q4 2023, a 41% increase compared to Q4 2022. Looking ahead, NeuroPace provided revenue guidance for 2024, projecting to reach between $73-$77 million. The company's growth strategies, including initiatives under Project CARE, are aimed at expanding access to its RNS System for epilepsy treatment.
Read more →NPCENeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
NeuroPace, Inc. announced its plans to report financial results for the fourth quarter and full year 2023 on March 5, 2024. The company, specialized in medical devices for epilepsy, aims to enhance patient care with its RNS System. A live webcast of the management conference call will also provide insights into the company’s performance and strategies. This marks a potentially significant moment for investors and stakeholders as they seek to understand the company’s trajectory.
Read more →NPCE▲ +12.9%on this news
NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates Preliminary unaudited revenue expected to be between $17.5 million and $18.0 million for Q4 2023 and b
NeuroPace, Inc. announced its preliminary unaudited revenue for Q4 2023, estimating between $17.5 million and $18.0 million, and full-year revenue of approximately $64.9 million to $65.4 million. The company has completed patient implant milestones ahead of schedule in its NAUTILUS trial, aimed at treating generalized epilepsy. Additionally, NeuroPace plans to launch its Project CARE in the first half of 2024, which seeks to expand community access to the RNS System. The company will present at the upcoming J.P. Morgan Healthcare Conference and plans to release full financial results in March 2024.
Read more →NPCENeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study
NeuroPace, Inc. has announced the early completion of patient enrollment in the NAUTILUS pivotal study, aimed at evaluating neuromodulation therapy for idiopathic generalized epilepsy (IGE). The study is significant as it is the first of its kind to explore this therapy for a condition that currently lacks effective treatment options. The completion of enrollment ahead of schedule reflects a strong interest from both patients and clinicians. If successful, NeuroPace's RNS System could be the first device-based treatment approved for this patient population, filling a critical gap in epilepsy care.
Read more →NPCE▲ +6.7%on this newsshared move
NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare Conference
NeuroPace, Inc. will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024. The event will take place in San Francisco, CA, and the presentation will be available via live webcast. NeuroPace focuses on improving the lives of epilepsy patients with its advanced RNS System, which provides personalized, real-time treatment for seizures.
Read more →NPCE▼ -8.7%on this news
NeuroPace to Leverage the Power of its RNS System’s Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration
NeuroPace, Inc. has announced a groundbreaking multi-year collaboration to utilize its RNS System's data analysis capabilities in a clinical trial context. The collaboration is expected to generate approximately $3.7 million, as the clinical-stage biotechnology company gains access to insights on biomarker changes in RNS System patients. This initiative is aimed at optimizing clinical trial execution and enhancing treatment strategies for individuals with epilepsy. The agreement involves several phases and aims to leverage the group's extensive data to improve patient outcomes.
Read more →NPCENeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting
NeuroPace, Inc. has announced its significant participation in the 77th American Epilepsy Society Annual Meeting in Orlando, where it will highlight its RNS System designed for epilepsy patients. The meeting features over 50 original scientific presentations focused on this brain-responsive platform, which aims to improve outcomes for individuals with drug-resistant epilepsy. Additionally, NeuroPace will host various events to engage with healthcare professionals and researchers in the field. This platform represents a novel approach in personalized treatment for epilepsy.
Read more →NPCENeuroPace to Present at the Piper Sandler 35th Annual Healthcare Conference
NeuroPace, Inc. announced its participation in the Piper Sandler 35th Annual Healthcare Conference, scheduled for November 28-30 in New York. CEO Joel Becker will present on November 28, followed by one-on-one meetings with investors. The company's RNS System, aimed at treating epilepsy, is the only commercially available brain-responsive platform providing personalized treatment. This engagement highlights NeuroPace's commitment to enhancing care for patients with drug-resistant epilepsy.
Read more →NPCEDocument NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance Third quarter 2023 revenue of $16.4 million, an increase of 47% year-over-year Full-year revenue guidance incr
NeuroPace, Inc. reported strong financial results for the third quarter of 2023, achieving revenues of $16.4 million, a substantial 47% increase compared to the previous year. The company has raised its full-year revenue guidance to between $62.5 million and $63.5 million, reflecting confidence in ongoing revenue growth. Additionally, cash burn was reduced to $2.2 million, further extending its runway. Key developments included FDA approval for new monitoring technology and progress in clinical trials, positioning the company for continued success in 2024.
Read more →NPCENeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
NeuroPace, Inc. reported impressive financial results for Q3 2023, with revenue reaching $16.4 million, a 47% increase compared to the same quarter last year. The company has raised its full-year revenue guidance to a range of $62.5 to $63.5 million, indicating strong growth momentum. Additionally, cash burn dropped significantly to $2.2 million. However, the company still faces a net loss of $7.3 million, and operating expenses remain high, reflecting ongoing investments in growth.
Read more →NPCENeuroPace Announces RNS System Enhancements Designed to Streamline Care
NeuroPace, Inc. has announced several enhancements to its RNS System aimed at improving patient care for those living with epilepsy. Among the updates are the upgraded nSight Platform for better data management and the FDA-approved Tablet Remote Monitor designed for ease of use. These advancements aim to enable clinicians to more effectively track and evaluate patient data, potentially optimizing treatment outcomes. The company anticipates commercial launch of the Tablet Remote Monitor in Q4 2023.
Read more →NPCENeuroPace to Report Third Quarter 2023 Financial Results on November 6, 2023
NeuroPace, Inc. has announced it will report its financial results for the third quarter of 2023 on November 6, 2023, followed by a conference call. The company's RNS System, aimed at treating epilepsy, continues to highlight its commitment to improving patient care. Interested investors can access the live and archived webcast of the conference call through NeuroPace's investor relations website. NeuroPace also acknowledges uncertainties and risks associated with its forward-looking statements.
Read more →NPCE▼ -5.4%on this news
NeuroPace to Participate in 2023 Cantor Fitzgerald Global Healthcare Conference
NeuroPace, Inc. announced its participation in the 2023 Cantor Fitzgerald Global Healthcare Conference, set for September 28, 2023, in New York City. During the conference, the company will engage in a fireside chat, discussing its innovative RNS System designed to treat epilepsy. A live webcast of the discussion will be available, along with an archived replay for later access. NeuroPace focuses on transforming the lives of individuals suffering from drug-resistant epilepsy through its personalized treatment solutions.
Read more →NPCE▲ +7.9%on this news· ran to +86% by day 3
NeuroPace to Participate in Upcoming Investor Conferences
NeuroPace, Inc. (NPCE) announced its participation in several upcoming investor conferences, including the Wells Fargo Healthcare Conference and the Morgan Stanley Global Healthcare Conference. Management, led by CEO Joel Becker and CFO Rebecca Kuhn, will engage in 1x1 meetings and discussions, indicating a proactive approach to investor relations. NeuroPace focuses on transforming the lives of epilepsy patients through its innovative RNS System, which provides personalized and real-time treatment.
Read more →NPCEDocument NeuroPace Reports Second Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance Second quarter 2023 revenue of $16.5 million increased 62% year-over-year Full-year revenue guidance increase
NeuroPace reported strong financial results for the second quarter of 2023, with total revenue reaching $16.5 million and a notable 62% increase year-over-year. The company also raised its full-year revenue guidance to between $59 million and $61 million, reflecting optimism about increasing utilization of its RNS System. Furthermore, cash burn was reduced significantly, and clinical trial enrollment is progressing as planned. Despite these positives, the company continues to face challenges, such as ongoing net losses and a decline in replacement implant revenue.
Read more →NPCENeuroPace Reports Second Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
NeuroPace, Inc. reported significant financial progress in its second quarter of 2023, with revenue of $16.5 million marking a 62% increase compared to the same period last year. The company raised its full-year revenue guidance to a range of $59-$61 million, reflecting strong demand for its RNS System. Cash burn was notably reduced to $4 million, supporting the company's cash runway. Despite the overall positive results, the net loss remains a concern, and the decline in replacement device revenue was expected as the company transitions to a second-generation product.
Read more →NPCENeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock Market
NeuroPace, Inc. announced the granting of a stock option to its newly appointed CEO, Joel Becker, allowing him to purchase 380,424 shares at an exercise price of $4.39. This grant, part of the company's 2023 Inducement Plan, is aimed at incentivizing Becker's role in transforming the lives of individuals with epilepsy. The shares will vest over approximately four years, with a quarter of the shares vesting in July 2024. NeuroPace is known for its innovative RNS System, which provides real-time treatment of seizures.
Read more →NPCENeuroPace to Report Second Quarter 2023 Financial Results on August 8, 2023
NeuroPace, Inc. is set to report its financial results for the second quarter of 2023 on August 8, 2023. The report will follow a conference call scheduled for 1:30 p.m. Pacific Time, which will be accessible to investors both live and via a recorded archive. NeuroPace is dedicated to improving the lives of individuals with epilepsy, particularly through its innovative RNS System, designed to deliver personalized treatment for seizure management.
Read more →NPCENeuroPace Announces CEO Transition
NeuroPace has announced the appointment of Joel Becker as the new President and CEO, effective July 10, 2023, following Mike Favet's departure after four years. Becker brings over 25 years of experience in the medical device sector, previously holding executive positions at Viking North Ventures and St. Jude Medical. The company's chairman expressed confidence in Becker's ability to drive the company's growth strategy and adoption of its RNS System for epilepsy treatment. Favet will assist during the transition as a consultant.
Read more →NPCENeuroPace Announces Addition of Kelley Nicholas as Vice President, Sales
NeuroPace, Inc. announced the appointment of Kelley Nicholas as Vice President of Sales as of May 22, 2023. With extensive experience in the medical device sector, Nicholas previously held key positions at Hologic and Thermo Fisher Scientific, where she drove significant growth and strategic initiatives. CEO Mike Favet expressed confidence in her ability to lead NeuroPace's sales and commercial program, thereby impacting the company’s mission to improve the lives of individuals living with epilepsy.
Read more →NPCEDocument NeuroPace Reports First Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance First quarter 2023 revenue increased 27% year-over-year to $14.5 million Full-year revenue guidance updated on
NeuroPace, Inc. reported its first quarter 2023 financial results, showing a 27% year-over-year increase in revenue to $14.5 million. The company raised its full-year revenue guidance to $52-$54 million, reflecting strong operational performance and optimized expense management. Despite the revenue growth, NeuroPace continued to face challenges with declining replacement implant revenue, resulting in a net loss of $10.4 million for the quarter. The company is maintaining momentum in its pivotal study for epilepsy and focusing on expanding its addressable market.
Read more →NPCENeuroPace Reports First Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
NeuroPace, Inc. reported a 27% year-over-year revenue increase for Q1 2023, totaling $14.5 million. The company has raised its full-year revenue guidance to $52-$54 million, showcasing strong commercial performance. While the enrollment in a pivotal epilepsy study continues, they face challenges with declining replacement implant revenue. Despite a minor decrease in net loss, the company remains focused on expense management and operational efficiency.
Read more →NPCENeuroPace to Report First Quarter 2023 Financial Results on May 4, 2023
NeuroPace, Inc. has announced that it will report its financial results for the first quarter of 2023 on May 4, 2023, after market close. The company, based in Mountain View, California, specializes in medical devices aimed at improving the lives of individuals with epilepsy. A conference call will be held following the financial report, which can be accessed via a live and archived webcast. NeuroPace's RNS System is recognized as a groundbreaking platform for providing personalized treatments for patients with epilepsy.
Read more →NPCENeuroPace to Present at the 22nd Annual Needham Virtual Healthcare Conference
NeuroPace, Inc. will participate in the 22nd Annual Needham Virtual Healthcare Conference, scheduled for April 17, 2023. The firm's management will present their innovative approaches to treating epilepsy and highlight the capabilities of their RNS System. This device, aimed at reducing seizure occurrences, represents a significant advancement in the treatment of drug-resistant epilepsy. The presentation is expected to showcase the potential of NeuroPace's technology to enhance patient outcomes.
Read more →NPCE▼ -11.2%on this news
NeuroPace Reports Fourth Quarter & Full Year 2022 Financial Results
NeuroPace, Inc. reported its fourth quarter and full-year financial results for 2022, showing a total revenue of $12.8 million in Q4, a 16% increase from the previous year. Despite growth in initial implant revenue and contributions from new product distributions, the company faced a higher net loss compared to the previous year. The firm anticipates revenue for 2023 to increase between 10% and 14% as it drives utilization of its RNS System and engages in further operational transitions. However, a decline in replacement implant revenue is expected as patients shift to the new RNS System.
Read more →NPCE▼ -11.2%on this news
Document NeuroPace Reports Fourth Quarter Full Year 2022 Financial Results Mountain View, Calif.
NeuroPace, Inc. reported its fourth quarter and full-year financial results for 2022, showing a revenue increase of 16% year-over-year in Q4. The company generated a total revenue of $12.8 million for the quarter and $45.5 million for the year. Despite the positive growth, NeuroPace faced challenges including an increase in net loss and a decline in gross margin. Looking ahead, the company forecasts a revenue growth of 10% to 14% for 2023, driven by continued utilization of their RNS System and contributions from partnerships.
Read more →NPCENeuroPace to Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023
NeuroPace, Inc. (Nasdaq: NPCE) has announced that it will report its financial results for the fourth quarter and full year of 2022 on March 2, 2023. The report will be followed by a conference call, beginning at 1:30 p.m. Pacific Time. NeuroPace specializes in medical devices aimed at managing epilepsy, notably through its RNS System, which delivers personalized treatments to patients. The webcast will be accessible for live and archived viewing for investors.
Read more →NPCENeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Revenue and Appoints Dr. Uri Geiger to Board of Directors Mountain View, Calif.
NeuroPace announced preliminary, unaudited revenue for Q4 and full-year 2022, showcasing continued business growth driven by its RNS System. The company also appointed Dr. Uri Geiger, highlighting his experience and impact on the Board of Directors. While the company is optimistic about expanding its market presence in drug-resistant epilepsy treatment, the preliminary financial results remain unaudited and subject to change.
Read more →NPCENeuroPace to Present at the 41st Annual J.P. Morgan Healthcare Conference
MOUNTAIN VIEW, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will be participating in the upcoming 41st Annual J.P. Morgan He
Read more →NPCE▲ +8.6%on this news
Document NeuroPace Reports Third Quarter 2022 Financial Results and Provides a Business Update Mountain View, Calif.
NeuroPace Reports Third Quarter 2022 Financial Results and Provides a Business Update Mountain View, Calif. -November 8, 2022 - NeuroPace, Inc. (Nasdaq NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today rep
Read more →NPCE▲ +8.6%on this news
NeuroPace Reports Third Quarter 2022 Financial Results and Provides a Business Update
MOUNTAIN VIEW, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the quarter ending September 30, 2022. Ach
Read more →NPCENeuroPace to Present at the 4th Annual Wolfe Research Healthcare Conference
MOUNTAIN VIEW, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will be participating in the upcoming 4th Annual Wolfe Research
Read more →NPCENeuroPace to Report Third Quarter 2022 Financial Results on November 8, 2022
MOUNTAIN VIEW, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter 2022 after m
Read more →NPCENeuroPace to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
MOUNTAIN VIEW, Calif. , Aug. 23, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will be participating in the upcoming Morgan Stanley 20th Annua
Read more →NPCENeuroPace Reports Second Quarter 2022 Financial Results and Provides a Business Update
MOUNTAIN VIEW, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the quarter ending June 30, 2022. Announce
Read more →NPCEDocument NeuroPace Reports Second Quarter 2022 Financial Results and Provides a Business Update Mountain View, Calif.
NeuroPace Reports Second Quarter 2022 Financial Results and Provides a Business Update Mountain View, Calif. -August 11, 2022 - NeuroPace, Inc. (Nasdaq NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today rep
Read more →NPCENeuroPace Announces Distribution Agreement with DIXI Medical USA, Provider of Intracranial Electrodes and Instruments for Neurosurgery
MOUNTAIN VIEW, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced that the company has entered into a commercialization agreement wit
Read more →NPCENeuroPace to Report Second Quarter 2022 Financial Results on August 11, 2022
MOUNTAIN VIEW, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the second quarter 2022 after
Read more →NPCENeuroPace to Present at the 2022 RBC Capital Markets Global Healthcare Conference
MOUNTAIN VIEW, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will be participating in the upcoming 2022 RBC Capital Markets
Read more →NPCEDocument NeuroPace Reports First Quarter 2022 Financial Results Mountain View, Calif.
NeuroPace Reports First Quarter 2022 Financial Results Mountain View, Calif. -May 12, 2022 - NeuroPace, Inc. (Nasdaq NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the qua
Read more →NPCENeuroPace Reports First Quarter 2022 Financial Results
MOUNTAIN VIEW, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the quarter ending March 31, 2022. Total re
Read more →NPCENeuroPace to Report First Quarter 2022 Financial Results on May 12, 2022
MOUNTAIN VIEW, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the first quarter 2021 aft
Read more →NPCE▼ -6.6%on this news
Document NeuroPace Reports Fourth Quarter Full Year 2021 Financial Results Mountain View, Calif.
NeuroPace Reports Fourth Quarter Full Year 2021 Financial Results Mountain View, Calif. -March 10, 2022 - NeuroPace, Inc. (Nasdaq NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial result
Read more →NPCE▼ -6.6%on this news
NeuroPace Reports Fourth Quarter & Full Year 2021 Financial Results
MOUNTAIN VIEW, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the fourth quarter and full year ended Dec
Read more →NPCE▼ -5.6%on this news
NeuroPace to Report Fourth Quarter and Full Year 2021 Financial Results and Present at the 11th Annual SVB Leerink Global Healthcare Conference
MOUNTAIN VIEW, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the fourth quarter and full
Read more →NPCE▲ +6.7%on this news
NeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2021 Revenue Mountain View, Calif.
NeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2021 Revenue Mountain View, Calif. January 11, 2022 NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announ
Read more →NPCENeuroPace to Present at 40th Annual J.P. Morgan Healthcare Conference
MOUNTAIN VIEW, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced that Mike Favet, CEO, Rebecca Kuhn, CFO and VP of Finance and Ad
Read more →NPCENeuroPace Reports Third Quarter 2021 Financial Results
MOUNTAIN VIEW, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the quarter ended September 30, 2021. Tota
Read more →NPCENeuroPace Receives IDE Approval to Initiate NAUTILUS Pivotal Study of its RNS System for Idiopathic Generalized Epilepsy
IDE study will be first to evaluate the effectiveness of brain-responsive neuromodulation to treat primary generalized epilepsy in patients aged 12 and older MOUNTAIN VIEW, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc., a medical technology company dedicated to trans
Read more →NPCEDocument NeuroPace Reports Third Quarter 2021 Financial Results Mountain View, Calif.
NeuroPace Reports Third Quarter 2021 Financial Results Mountain View, Calif. -November 10, 2021 - NeuroPace, Inc. (Nasdaq NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for th
Read more →NPCENeuroPace to Report Third Quarter 2021 Financial Results on November 10, 2021
MOUNTAIN VIEW, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the third quarter of 2021 a
Read more →NPCENeuroPace Announces Addition of Lisa Andrade to the Board
MOUNTAIN VIEW, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc., (Nasdaq:NPCE) a medical technology company dedicated to transforming the lives of people suffering from epilepsy, today announced the addition of Lisa Andrade to its Board of Directors. Simultaneously, the
Read more →NPCENeuroPace to Participate in Upcoming Conferences
MOUNTAIN VIEW, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported that the company will be participating in three upcoming conferen
Read more →NPCENeuroPace Reports Second Quarter 2021 Financial Results
MOUNTAIN VIEW, Calif. , Aug. 12, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the quarter ended June 30, 2021. Total re
Read more →NPCEDocument NeuroPace Reports Second Quarter 2021 Financial Results Mountain View, Calif.
NeuroPace Reports Second Quarter 2021 Financial Results Mountain View, Calif. -August 12, 2021 - NeuroPace, Inc. (Nasdaq NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the
Read more →NPCENeuroPace To Report Second Quarter 2021 Financial Results on August 12, 2021
MOUNTAIN VIEW, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the second quarter of 2021
Read more →NPCENeuroPace Awarded Five-Year NIH Grant Funding of More than $9M to Study RNS System in Patients with Lennox-Gastaut Syndrome
Feasibility IDE study will be the first to evaluate responsive neuromodulation for a severe and disabling childhood-onset epilepsy MOUNTAIN VIEW, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc., a medical technology company dedicated to transforming the lives of people
Read more →NPCEDocument NeuroPace Reports First Quarter 2021 Financial Results and Provides 2021 Financial Guidance Mountain View, Calif.
NeuroPace Reports First Quarter 2021 Financial Results and Provides 2021 Financial Guidance Mountain View, Calif. - June 3, 2021 - NeuroPace, Inc. (Nasdaq NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today
Read more →NPCENeuroPace Reports First Quarter 2021 Financial Results and Provides 2021 Financial Guidance
MOUNTAIN VIEW, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the quarter ended March 31, 2021. Total re
Read more →NPCENeuroPace To Report First Quarter 2021 Financial Results on June 3, 2021
MOUNTAIN VIEW, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the first quarter of 2021 be
Read more →NPCENeuroPace, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
MOUNTAIN VIEW, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from epilepsy, today announced the closing of its initial publ
Read more →NPCENeuroPace, Inc. Announces Pricing of Initial Public Offering
MOUNTAIN VIEW, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from epilepsy, today announced the pricing of its initial publ
Read more →Competitive Position
How NPCE ranks across every disease it competes inCompetitive Position is a premium feature
See how NPCE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial